Healthcare Industry News: MammaPrint
News Release - July 9, 2012
Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of FinanceIRVINE, Calif. and AMSTERDAM, July 9, 2012 -- (Healthcare Sales & Marketing Network) -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced a key addition to their executive team with the appointment of Glen Fredenberg as CFO and Vice President of Finance.
"It is a very exciting time with the recent launch of Agendia's Symphony suite of tests in an FFPE format as well as the ColoPrint recurrence test for stage II colon cancer prognosis and prediction," said Fredenberg. "As a cohesive executive team, we are poised to bring Agendia to the next level."
Fredenberg has more than twenty years of experience with financial management and corporate governance, primarily in the clinical laboratory industry. Previously, Fredenberg was the CFO at US Labs in Irvine, California, which grew from $1 million in revenue to more than $80 million in revenue and was then successfully sold to LabCorp in 2005. Most recently, he has been the CFO at Clarient in Aliso Viejo, California, which has grown to $140 million in revenue and was successfully sold to GE Healthcare in late 2010. Fredenberg holds a Bachelor of Science in Business Administration from California State University, Fullerton, and is a licensed Certified Public Accountant.
"The addition of Glen Fredenberg to our executive team will have a tremendous impact on Agendia and will accelerate our progress in the molecular diagnostics industry," said David Macdonald, CEO of Agendia. "Our team is focused on the commercialization of our current breast and colon cancer Symphony suite of tests as well as the development of our personalized medicine pipeline."
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.
For more information, please visit www.agendia.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.